Patents by Inventor Xiaoyan Jiang
Xiaoyan Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124616Abstract: A graft copolymer and a preparation method and use thereof. The method for preparing a graft copolymer includes: dissolving an N-ethyl-2-pyrrolidinone-substituted flavan-3-ol (EPSF) and a starch in a polar organic solvent, to obtain a raw material solution; and mixing the raw material solution with ascorbic acid and hydrogen peroxide to obtain a mixture, and subjecting the mixture to a grafting reaction, to obtain the graft copolymer.Type: ApplicationFiled: July 24, 2023Publication date: April 18, 2024Applicant: ANHUI AGRICULTURAL UNIVERSITYInventors: QI CHEN, XIAOCHUN WAN, XIAOYAN GUO, ZONGDE JIANG, XIAOQIAN WANG, YUQIN XIA
-
Publication number: 20240111406Abstract: A processing method includes displaying at least two windows in at least two split-screen regions based on a split-screen command, obtaining an input operation for a target window in the at least two windows, determining adjustment parameters of a correlation window related to the target window and among the at least two windows in response to the input operation, and adjusting the correlation window based on the adjustment parameters. The region of each of the at least two windows corresponds to a split-screen region of the at least two split-screen regions. Each of the at least two windows includes an interactive interface. The correlation window before the correlation window adjustment is different from the correlation window after the correlation window adjustment.Type: ApplicationFiled: September 11, 2023Publication date: April 4, 2024Inventors: Yiming JIANG, Xiaoyan SHI
-
Patent number: 11946092Abstract: A method for producing 2-keto-3-deoxygluconate (KDG) from 2-(acetylamino)-2-deoxy-D-gluconic acid (GlcNAc1A) by two enzymes; GlcNAc1A is converted to KDG by incubating GlcNAc1A with a deacetylase OngB at 25° C. for 4-12 h and then with a deaminase OngC at 25° C. for another 10-15 h; it constructs two engineered E. coli/pET22b-ongB (carrying the ongB gene) and E. coli/pET22b-ongC (carrying the ongC gene) strains to prepare recombinant proteins OngB and OngC, respectively; at the action of these two enzymes, OngB and OngC, GlcNAc1A is converted to KDG, which solves the bottleneck of GlcNAc1A utilization during the bioconversion of chitin; the KDG is an important metabolic intermediate to synthesize furan derivatives, herbicides, food additives and other industrially important chemical compounds, having wide industrial applications.Type: GrantFiled: October 31, 2022Date of Patent: April 2, 2024Assignee: SHANDONG UNIVERSITYInventors: Yuzhong Zhang, Pingyi Li, Wenxin Jiang, Xiulan Chen, Yishuo Zhang, Xiaoyan Song
-
Patent number: 11947817Abstract: Methods, systems, and apparatus, including computer programs encoded on computer-storage media, for memory mapping to enhance data cube performance. In some implementations, a system accesses a data set that includes data to be processed into a data cube. The system generates a memory-mapped data cube that includes a plurality of files including different segments of the data cube. Generating the memory-mapped data cube includes allocating memory-mapped buffers in non-volatile data storage and responding to subsequent memory allocation requests with addresses for the buffers such that components of the data cube are accumulated in the buffers. The memory-mapped data cube is loaded by storing the files of the data cube in disk-based storage, mapping the stored files of the data cube to virtual memory addresses, and caching portions of the data cube in random-access memory.Type: GrantFiled: November 15, 2021Date of Patent: April 2, 2024Assignee: MicroStrategy IncorporatedInventors: Qianping Jiang, Cheng Guo, Rixin Liao, Cezary Raczko, Xiaoyan Yu
-
Publication number: 20240082306Abstract: Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a ?C chain or intracellular region thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.Type: ApplicationFiled: December 7, 2021Publication date: March 14, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Gong CHEN, Tingting GUO, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Patent number: 11924080Abstract: Some embodiments provide a method of identifying packet latency in a software defined datacenter (SDDC) that includes a network and multiple host computers executing multiple machines. At a first host computer, the method identifies and stores (i) multiple time values associated with several packet processing operations performed on a particular packet sent by a first machine executing on the first host computer, and (ii) a time value associated with packet transmission through the SDDC network from the first host computer to a second host computer that is a destination of the particular packet. The method provides the stored time values to a set of one or more controllers to process to identify multiple latencies experienced by multiple packets processed in the SDDC.Type: GrantFiled: March 21, 2022Date of Patent: March 5, 2024Assignee: VMware LLCInventors: Haoran Chen, Ming Shu, Xi Cheng, Feng Pan, Xiaoyan Jin, Caixia Jiang, Qiong Wang, Qi Wu
-
Publication number: 20240052029Abstract: Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.Type: ApplicationFiled: January 12, 2022Publication date: February 15, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Gong CHEN, Tingting GUO, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN, Guokun LI, Jing ZHANG, Huifang SUN
-
Publication number: 20240041806Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.Type: ApplicationFiled: September 1, 2021Publication date: February 8, 2024Applicant: Tsubota Laboratory, Inc.Inventors: Kazuo Tsubota, Toshihide Kurihara, Shinichi Ikeda, Kiwako Mori, Xiaoyan Jiang
-
Publication number: 20240043532Abstract: Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with NKG2A expression.Type: ApplicationFiled: November 18, 2021Publication date: February 8, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Tingting GUO, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20240018236Abstract: The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.Type: ApplicationFiled: December 7, 2021Publication date: January 18, 2024Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Xiaoyan JIANG, Gong CHEN, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20240009308Abstract: Provided is a chimeric antigen receptor, comprising a ligand-binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. The co-stimulatory domain comprises an intracellular region of an NK-activated receptor or a ligand thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a use thereof in treatment of diseases, such as cancers, autoimmune diseases, and infections.Type: ApplicationFiled: September 9, 2021Publication date: January 11, 2024Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230399398Abstract: The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.Type: ApplicationFiled: October 29, 2021Publication date: December 14, 2023Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Xiaoyan JIANG, Gong CHEN, Jiangtao REN, Xiaohong He, Yanbin Wang, Lu HAN
-
Publication number: 20230390336Abstract: Provided is an engineered immune cell. The cell expresses a chimeric antigen receptor comprising an antigen-binding region. The antigen-binding region comprises an anti-CD7 antibody, and the expression of endogenous CD7, at least one TCR/CD3 gene, and at least one MHC-II related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of diseases associated with CD7 expression.Type: ApplicationFiled: October 29, 2021Publication date: December 7, 2023Applicant: BIOHENG THERAPEUTICS LIMITEDInventors: Yali ZHOU, Xiaoyan JIANG, Gong CHEN, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230364441Abstract: A device and a method for inhibiting thinning of a choroid. A choroidal thinning inhibiting device including a light source that emits violet light having a wavelength within a range from 360 nm to 400 nm, the choroidal thinning inhibiting device inhibiting thinning of a choroid by irradiation with the violet light. This device may further include a control mechanism that controls an irradiance and an irradiation time of the violet light, can be applied to ocular diseases selected from age-related macular degeneration, glaucoma, diabetic retinopathy, macular edema, eye strain, retinal vascular occlusion, triangle syndrome, central serous chorioretinopathy, retinitis pigmentosa, presbyopia, cataracts, and the like that are based on inadequate blood flow or reduced blood flow, and can be expected to prevent and treat such ocular diseases.Type: ApplicationFiled: September 16, 2021Publication date: November 16, 2023Applicant: TSUBOTA LABORATORY, INC.Inventors: Xiaoyan JIANG, Kiwako MORI, Toshihide KURIHARA, Kazuo TSUBOTA
-
Patent number: 11808242Abstract: A high-pressure fuel pump includes a drive shaft, and a vane pump and a plunger pump which are driven by the drive shaft. The vane pump is configured to supply pre-pressurized fuel to the plunger pump. The drive shaft includes a cam configured to drive a piston rod of the plunger pump such that the plunger pump alternately executes a fuel suction stroke and a fuel discharge stroke. The drive shaft further includes a shaft portion for driving a rotor of the vane pump. The vane pump is configured such that for each fuel suction stroke of the plunger pump the vane pump provides a fuel supply cycle that is advanced by a phase angle relative to the fuel suction stroke.Type: GrantFiled: August 5, 2021Date of Patent: November 7, 2023Assignee: Robert Bosch GmbHInventors: Ziang Dong, Xiaoyan Jiang, Yingsa Huang
-
Publication number: 20230270858Abstract: A chimeric antigen receptor, containing a ligand binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain, the co-stimulatory domain containing CD94 and/or LT? intracellular regions. The present invention further relates to engineered immune cells containing such a chimeric antigen receptor, and uses thereof in the treatment of diseases, such as cancer, autoimmune diseases, and infections.Type: ApplicationFiled: August 19, 2021Publication date: August 31, 2023Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230248768Abstract: Provided is an engineered immune cell. The expressions of at least one MHC related gene and at least one NK activating receptor binding molecule are suppressed or silenced, so as to suppress the killing of the engineered immune cell by NK cells. Also provided are a pharmaceutical composition comprising the engineered immune cell and use of the engineered immune cell in preparation of drugs for treatment of cancer, infection, or autoimmune diseases.Type: ApplicationFiled: July 14, 2021Publication date: August 10, 2023Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Publication number: 20230242661Abstract: Provided is an NK inhibitory molecule, which includes one or more NK inhibitory ligands, a transmembrane domain and a co-stimulatory domain, wherein the NK inhibitory ligand specifically binds to NK inhibitory receptors to inhibit the killing of NK cells against the engineered immune cells expressing the NK inhibitory molecule. Also provided is an engineered immune cell expressing the NK inhibitory molecule of the present invention, wherein the expression of at least one MHC-related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of cancers, infections or autoimmune diseases. Compared to the traditional engineered immune cells, the engineered immune cell can significantly inhibit the killing effect of NK cells in a subject, thereby reducing the risk of HvGD.Type: ApplicationFiled: June 10, 2021Publication date: August 3, 2023Inventors: Yali ZHOU, Gong CHEN, Xiaoyan JIANG, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN
-
Patent number: 11615346Abstract: Embodiments of the present disclosure provide a method and system for training a model by using training data. The training data includes a plurality of samples, each sample includes N features, and features in the plurality of samples form N feature columns, and the method includes: determining an importance value of each of the N feature columns; determining whether the importance value of each of the N feature columns satisfies a threshold condition; performing a dimension reduction on M feature columns to generate P feature columns in response to the determination that the importance values of the M feature columns do not satisfy the threshold condition, wherein M<N and P<M; merging (N?M) feature columns having importance values that satisfy the threshold condition and the generated P feature columns to obtain (N?M+P) feature columns; and training the model based on the training data including the (N?M+P) feature columns.Type: GrantFiled: August 24, 2018Date of Patent: March 28, 2023Assignee: Alibaba Group Holding LimitedInventors: Bin Dai, Shen Li, Xiaoyan Jiang, Xu Yang, Yuan Qi, Wei Chu, Shaomeng Wang, Zihao Fu
-
Patent number: 11551036Abstract: The present disclosure provides methods and an apparatuses for building a data identification model. One exemplary method for building a data identification model includes: performing logistic regression training using training samples to obtain a first model, the training samples comprising positive and negative samples; sampling the training samples proportionally to obtain a first training sample set; identifying the positive samples using the first model, and selecting a second training sample set from positive samples that have identification results after being identified using the first model; and performing Deep Neural Networks (DNN) training using the first training sample set and the second training sample set to obtain a final data identification model. The methods and the apparatuses of the present disclosure improve the stability of data identification models.Type: GrantFiled: August 24, 2018Date of Patent: January 10, 2023Assignee: Alibaba Group Holding LimitedInventors: Xiaoyan Jiang, Xu Yang, Bin Dai, Wei Chu